col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Publishing House: Just Medical Media, Ltd.
  original article Journal Date Title Authors All Authors
1 [GO] Drugs in Context 2021―Oct―05 Vitamins, supplements and COVID-19: a review of currently available evidence Lauren Speakman, Sarah Michienzi, Melissa Badowski
2 [GO] Drugs in Context 2021―Jun―23 Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, et al. (+5)
3 [GO] Drugs in Context 2021―Jun―08 Dermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic Tiago Torres, Marta Pereira, Maria João Paiva Lopes, Clarisse Rebelo, Pedro Andrade, Martinha Henrique, et al. (+7)
4 [GO] Drugs in Context 2021―May―24 The UK approach to COVID-19 vaccination: why was it so different? Peter MB English
5 [GO] Drugs in Context 2021―Mar―23 The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study Sergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, Lyudmila Yu Akhieva, Elena I Kvasova, Francisco Harrison, et al. (+5)
6 [GO] Drugs in Context 2021―Feb―15 The race to a COVID-19 vaccine: opportunities and challenges in development and distribution Rodrigo M Burgos, Melissa E Badowski, Emily Drwiega, Samaneh Ghassemi, Nikki Griffith, Fischer Herald, et al. (+3)
7 [GO] Drugs in Context 2021―Jan―29 Current treatment in COVID-19 disease: a rapid review Miguel Rodriguez-Guerra, Preeti Jadhav, Timothy J Vittorio
8 [GO] Drugs in Context 2020―Sep―16 Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol Teodoro Iturbe-Hernandez, Luis García de Guadiana Romualdo, Ignacio Gil Ortega, Antonio Martínez Francés, Olga Meca Birlanga, Juan José Cerezo-Manchado
9 [GO] Drugs in Context 2020―Jun―29 Coronavirus disease 2019 (COVID-19): latest developments in potential treatments Kam Lun Hon, Karen Ka Yan Leung, Alexander KC Leung, Su Yun Qian, Vivian PY Chan, Patrick Ip, Ian CK Wong
10 [GO] Drugs in Context 2020―Jun―20 Can vitamins and/or supplements provide hope against coronavirus? Sarah M Michienzi, Melissa E Badowski
11 [GO] Drugs in Context 2020―Jun―10 Neurological features of COVID-19 and their treatment: a review Daniele Orsucci, Elena Caldarazzo Ienco, Gianpaolo Nocita, Alessandro Napolitano, Marco Vista
12 [GO] Drugs in Context 2020―May―23 A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic Matteo Bassetti, Paolo Pelosi, Chiara Robba, Antonio Vena, Daniele Roberto Giacobbe
13 [GO] Drugs in Context 2020―May―20 The journey of remdesivir: from Ebola to COVID-19 Joe Pardo, Ashutosh M Shukla, Gajapathiraju Chamarthi, Asmita Gupte
14 [GO] Drugs in Context 2020―May―17 Pharmacological treatment of COVID-19: lights and shadows Francesco Menzella, Mirella Biava, Chiara Barbieri, Francesco Livrieri, Nicola Facciolongo
15 [GO] Drugs in Context 2020―May―13 Psoriasis, biologic therapy, and the pandemic of the 21st century Miguel Nogueira, Ron Vender, Tiago Torres
16 [GO] Drugs in Context 2020―May―10 Facing the COVID-19 outbreak in children with cancer Antonio Ruggiero, Alberto Romano, Giorgio Attinà
17 [GO] Drugs in Context 2020―Apr―27 Chloroquine and hydroxychloroquine in the context of COVID-19 Ashutosh M Shukla, Lennox K Archibald, Aparna Wagle Shukla, Hiren J Mehta, Kartikeya Cherabuddi


[de][en]

Last change 2021―Sep―04 16:13:39 UTC

© Daten-Quadrat 2021       Done in 0.005 sec